[{"orgOrder":0,"company":"Jiangsu Simcere Pharmaceutical","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Protein","year":"2016","type":"Inapplicable","leadProduct":"Abatacept","moa":"T-lymphocyte activation antigen CD86 | T-lymphocyte activation antigen CD80","graph1":"Immunology","graph2":"Phase III","graph3":"Jiangsu Simcere Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Jiangsu Simcere Pharmaceutical \/ Bristol Myers Squibb","highestDevelopmentStatusID":"10","companyTruncated":"Jiangsu Simcere Pharmaceutical \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Jiangsu Simcere Pharmaceutical","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Protein","year":"2016","type":"Inapplicable","leadProduct":"Abatacept","moa":"T-lymphocyte activation antigen CD86 | T-lymphocyte activation antigen CD80","graph1":"Immunology","graph2":"Phase III","graph3":"Jiangsu Simcere Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Jiangsu Simcere Pharmaceutical \/ Bristol Myers Squibb","highestDevelopmentStatusID":"10","companyTruncated":"Jiangsu Simcere Pharmaceutical \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"INDIA","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Abatacept","moa":"T-lymphocyte activation antigen CD86 | T-lymphocyte activation antigen CD80","graph1":"Immunology","graph2":"Phase I","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"University of Erlangen-N\u00fcrnberg Medical School","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"GERMANY","productType":"Protein","year":"2016","type":"Inapplicable","leadProduct":"Abatacept","moa":"T-lymphocyte activation antigen CD86 | T-lymphocyte activation antigen CD80","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"University of Erlangen-N\u00fcrnberg Medical School","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Erlangen-N\u00fcrnberg Medical School \/ Bristol Myers Squibb","highestDevelopmentStatusID":"10","companyTruncated":"University of Erlangen-N\u00fcrnberg Medical School \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"University Hospital, Brest","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"FRANCE","productType":"Protein","year":"2018","type":"Inapplicable","leadProduct":"Abatacept","moa":"T-lymphocyte activation antigen CD86 | T-lymphocyte activation antigen CD80","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"University Hospital, Brest","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University Hospital, Brest \/ Bristol Myers Squibb","highestDevelopmentStatusID":"10","companyTruncated":"University Hospital, Brest \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"University Medical Center Groningen","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Protein","year":"2014","type":"Inapplicable","leadProduct":"Abatacept","moa":"T-lymphocyte activation antigen CD86 | T-lymphocyte activation antigen CD80","graph1":"Immunology","graph2":"Phase III","graph3":"University Medical Center Groningen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University Medical Center Groningen \/ Bristol Myers Squibb","highestDevelopmentStatusID":"10","companyTruncated":"University Medical Center Groningen \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Cambridge University Hospitals NHS Foundation Trust","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Protein","year":"2017","type":"Inapplicable","leadProduct":"Abatacept","moa":"T-lymphocyte activation antigen CD86 | T-lymphocyte activation antigen CD80","graph1":"Immunology","graph2":"Phase II","graph3":"Cambridge University Hospitals NHS Foundation Trust","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cambridge University Hospitals NHS Foundation Trust \/ Bristol Myers Squibb","highestDevelopmentStatusID":"8","companyTruncated":"Cambridge University Hospitals NHS Foundation Trust \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Arthritis & Rheumatic Disease Specialties Research","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2011","type":"Inapplicable","leadProduct":"Abatacept","moa":"T-lymphocyte activation antigen CD86 | T-lymphocyte activation antigen CD80","graph1":"Immunology","graph2":"Phase III","graph3":"Arthritis & Rheumatic Disease Specialties Research","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Arthritis & Rheumatic Disease Specialties Research \/ Bristol Myers Squibb","highestDevelopmentStatusID":"10","companyTruncated":"Arthritis & Rheumatic Disease Specialties Research \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"University of California, Los Angeles","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2012","type":"Inapplicable","leadProduct":"Abatacept","moa":"T-lymphocyte activation antigen CD86 | T-lymphocyte activation antigen CD80","graph1":"Immunology","graph2":"Phase IV","graph3":"University of California, Los Angeles","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of California, Los Angeles \/ Bristol Myers Squibb","highestDevelopmentStatusID":"11","companyTruncated":"University of California, Los Angeles \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"University of California, Los Angeles","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2015","type":"Inapplicable","leadProduct":"Abatacept","moa":"T-lymphocyte activation antigen CD86 | T-lymphocyte activation antigen CD80","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"University of California, Los Angeles","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of California, Los Angeles \/ Bristol Myers Squibb","highestDevelopmentStatusID":"7","companyTruncated":"University of California, Los Angeles \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"University of South Florida","sponsor":"Cleveland Clinic | Bristol Myers Squibb | University of Pennsylvania | National Institutes of Health | National Institute of Arthritis and Musculoskeletal and Skin Diseases","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Protein","year":"2014","type":"Inapplicable","leadProduct":"Abatacept","moa":"T-lymphocyte activation antigen CD86 | T-lymphocyte activation antigen CD80","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"University of South Florida","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"University of South Florida \/ Cleveland Clinic | Bristol Myers Squibb | University of Pennsylvania | National Institutes of Health | National Institute of Arthritis and Musculoskeletal and Skin Diseases","highestDevelopmentStatusID":"10","companyTruncated":"University of South Florida \/ Cleveland Clinic | Bristol Myers Squibb | University of Pennsylvania | National Institutes of Health | National Institute of Arthritis and Musculoskeletal and Skin Diseases"},{"orgOrder":0,"company":"Johns Hopkins University","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2017","type":"Inapplicable","leadProduct":"Abatacept","moa":"T-lymphocyte activation antigen CD86 | T-lymphocyte activation antigen CD80","graph1":"Immunology","graph2":"Phase I","graph3":"Johns Hopkins University","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Johns Hopkins University \/ Bristol Myers Squibb","highestDevelopmentStatusID":"6","companyTruncated":"Johns Hopkins University \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Arthritis & Rheumatism Associates, P.C.","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2018","type":"Inapplicable","leadProduct":"Abatacept","moa":"T-lymphocyte activation antigen CD86 | T-lymphocyte activation antigen CD80","graph1":"Immunology","graph2":"Phase II","graph3":"Arthritis & Rheumatism Associates, P.C.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Arthritis & Rheumatism Associates, P.C. \/ Bristol Myers Squibb","highestDevelopmentStatusID":"8","companyTruncated":"Arthritis & Rheumatism Associates, P.C. \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Brigham and Women's Hospital","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2014","type":"Inapplicable","leadProduct":"Abatacept","moa":"T-lymphocyte activation antigen CD86 | T-lymphocyte activation antigen CD80","graph1":"Dermatology","graph2":"Phase I","graph3":"Brigham and Women's Hospital","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Brigham and Women's Hospital \/ Bristol Myers Squibb","highestDevelopmentStatusID":"6","companyTruncated":"Brigham and Women's Hospital \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Boston Children's Hospital","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Abatacept","moa":"T-lymphocyte activation antigen CD86 | T-lymphocyte activation antigen CD80","graph1":"Immunology","graph2":"Phase II","graph3":"Boston Children's Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boston Children's Hospital \/ Bristol Myers Squibb","highestDevelopmentStatusID":"8","companyTruncated":"Boston Children's Hospital \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Roswell Park Cancer Institute","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2018","type":"Inapplicable","leadProduct":"Abatacept","moa":"T-lymphocyte activation antigen CD86 | T-lymphocyte activation antigen CD80","graph1":"Oncology","graph2":"Phase II","graph3":"Roswell Park Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Roswell Park Cancer Institute \/ Bristol Myers Squibb","highestDevelopmentStatusID":"8","companyTruncated":"Roswell Park Cancer Institute \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Children's Hospital Medical Center, Cincinnati","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Abatacept","moa":"T-lymphocyte activation antigen CD86 | T-lymphocyte activation antigen CD80","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Children's Hospital Medical Center, Cincinnati","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Children's Hospital Medical Center, Cincinnati \/ Bristol Myers Squibb","highestDevelopmentStatusID":"8","companyTruncated":"Children's Hospital Medical Center, Cincinnati \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Oklahoma Medical Research Foundation","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2014","type":"Inapplicable","leadProduct":"Abatacept","moa":"T-lymphocyte activation antigen CD86 | T-lymphocyte activation antigen CD80","graph1":"Immunology","graph2":"Phase II","graph3":"Oklahoma Medical Research Foundation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oklahoma Medical Research Foundation \/ Bristol Myers Squibb","highestDevelopmentStatusID":"8","companyTruncated":"Oklahoma Medical Research Foundation \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Oregon Health and Science University","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2011","type":"Inapplicable","leadProduct":"Abatacept","moa":"T-lymphocyte activation antigen CD86 | T-lymphocyte activation antigen CD80","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Oregon Health and Science University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Oregon Health and Science University \/ Bristol Myers Squibb","highestDevelopmentStatusID":"8","companyTruncated":"Oregon Health and Science University \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Vanderbilt University Medical Center","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2014","type":"Inapplicable","leadProduct":"Abatacept","moa":"T-lymphocyte activation antigen CD86 | T-lymphocyte activation antigen CD80","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Vanderbilt University Medical Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Vanderbilt University Medical Center \/ Bristol Myers Squibb","highestDevelopmentStatusID":"8","companyTruncated":"Vanderbilt University Medical Center \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"University of Washington","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2019","type":"Inapplicable","leadProduct":"Abatacept","moa":"T-lymphocyte activation antigen CD86 | T-lymphocyte activation antigen CD80","graph1":"Immunology","graph2":"Phase IV","graph3":"University of Washington","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"University of Washington \/ Bristol Myers Squibb","highestDevelopmentStatusID":"11","companyTruncated":"University of Washington \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Benaroya Research Institute","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"U.S.A","productType":"Protein","year":"2011","type":"Inapplicable","leadProduct":"Abatacept","moa":"T-lymphocyte activation antigen CD86 | T-lymphocyte activation antigen CD80","graph1":"Rheumatology","graph2":"Phase I","graph3":"Benaroya Research Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Benaroya Research Institute \/ Bristol Myers Squibb","highestDevelopmentStatusID":"6","companyTruncated":"Benaroya Research Institute \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Ono Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2013","type":"Inapplicable","leadProduct":"Abatacept","moa":"T-lymphocyte activation antigen CD86 | T-lymphocyte activation antigen CD80","graph1":"Immunology","graph2":"Phase III","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bristol Myers Squibb \/ Ono Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Bristol Myers Squibb \/ Ono Pharmaceutical"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2013","type":"Inapplicable","leadProduct":"Abatacept","moa":"T-lymphocyte activation antigen CD86 | T-lymphocyte activation antigen CD80","graph1":"Immunology","graph2":"Phase III","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2018","type":"Inapplicable","leadProduct":"Abatacept","moa":"T-lymphocyte activation antigen CD86 | T-lymphocyte activation antigen CD80","graph1":"Immunology","graph2":"Phase IV","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2017","type":"Inapplicable","leadProduct":"Abatacept","moa":"T-lymphocyte activation antigen CD86 | T-lymphocyte activation antigen CD80","graph1":"Immunology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"Massachusetts General Hospital","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Abatacept","moa":"T-lymphocyte activation antigen CD86 | T-lymphocyte activation antigen CD80","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Massachusetts General Hospital","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Massachusetts General Hospital \/ Bristol Myers Squibb","highestDevelopmentStatusID":"10","companyTruncated":"Massachusetts General Hospital \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Abatacept","moa":"||T-lymphocyte activation antigen CD86 | T-lymphocyte activation antigen CD80","graph1":"Immunology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Abatacept","moa":"T-lymphocyte activation antigen CD86 | T-lymphocyte activation antigen CD80","graph1":"Immunology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Abatacept","moa":"T-lymphocyte activation antigen CD86 | T-lymphocyte activation antigen CD80","graph1":"Immunology","graph2":"Approved FDF","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"NYU Langone Health","sponsor":"Dartmouth-Hitchcock Medical Center | Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2018","type":"Inapplicable","leadProduct":"Abatacept","moa":"T-lymphocyte activation antigen CD86 | T-lymphocyte activation antigen CD80","graph1":"Immunology","graph2":"Phase IV","graph3":"NYU Langone Health","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"NYU Langone Health \/ Dartmouth-Hitchcock Medical Center | Bristol Myers Squibb","highestDevelopmentStatusID":"11","companyTruncated":"NYU Langone Health \/ Dartmouth-Hitchcock Medical Center | Bristol Myers Squibb"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Abatacept","moa":"T-lymphocyte activation antigen CD86 | T-lymphocyte activation antigen CD80","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2010","type":"Inapplicable","leadProduct":"Abatacept","moa":"T-lymphocyte activation antigen CD86 | T-lymphocyte activation antigen CD80","graph1":"Immunology","graph2":"Phase IV","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2011","type":"Inapplicable","leadProduct":"Abatacept","moa":"T-lymphocyte activation antigen CD86 | T-lymphocyte activation antigen CD80","graph1":"Immunology","graph2":"Phase IV","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Columbia University","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2018","type":"Inapplicable","leadProduct":"Abatacept","moa":"T-lymphocyte activation antigen CD86 | T-lymphocyte activation antigen CD80","graph1":"Immunology","graph2":"Phase IV","graph3":"Columbia University","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Columbia University \/ Bristol Myers Squibb","highestDevelopmentStatusID":"11","companyTruncated":"Columbia University \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2010","type":"Inapplicable","leadProduct":"Abatacept","moa":"T-lymphocyte activation antigen CD86 | T-lymphocyte activation antigen CD80","graph1":"Immunology","graph2":"Phase IV","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2016","type":"Inapplicable","leadProduct":"Abatacept","moa":"T-lymphocyte activation antigen CD86 | T-lymphocyte activation antigen CD80","graph1":"Immunology","graph2":"Phase III","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2017","type":"Inapplicable","leadProduct":"Abatacept","moa":"T-lymphocyte activation antigen CD86 | T-lymphocyte activation antigen CD80","graph1":"Immunology","graph2":"Phase III","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Cleveland Clinic","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2014","type":"Inapplicable","leadProduct":"Abatacept","moa":"T-lymphocyte activation antigen CD86 | T-lymphocyte activation antigen CD80","graph1":"Immunology","graph2":"Phase II","graph3":"Cleveland Clinic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Cleveland Clinic \/ Bristol Myers Squibb","highestDevelopmentStatusID":"8","companyTruncated":"Cleveland Clinic \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"NYU Langone Health","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Protein","year":"2012","type":"Inapplicable","leadProduct":"Abatacept","moa":"T-lymphocyte activation antigen CD86 | T-lymphocyte activation antigen CD80","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"NYU Langone Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"NYU Langone Health \/ Bristol Myers Squibb","highestDevelopmentStatusID":"6","companyTruncated":"NYU Langone Health \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Kashiv BioSciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"Abatacept","moa":"T-lymphocyte activation antigen CD86 | T-lymphocyte activation antigen CD80","graph1":"Immunology","graph2":"Phase I","graph3":"Kashiv BioSciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Kashiv BioSciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Kashiv BioSciences \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Abatacept","moa":"||T-lymphocyte activation antigen CD86 | T-lymphocyte activation antigen CD80","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Abatacept","moa":"T-lymphocyte activation antigen CD86 | T-lymphocyte activation antigen CD80","graph1":"Immunology","graph2":"Phase IV","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Kashiv BioSciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"Abatacept","moa":"T-lymphocyte activation antigen CD86 | T-lymphocyte activation antigen CD80","graph1":"Immunology","graph2":"Phase I","graph3":"Kashiv BioSciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Kashiv BioSciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Kashiv BioSciences \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2013","type":"Inapplicable","leadProduct":"Abatacept","moa":"T-lymphocyte activation antigen CD86 | T-lymphocyte activation antigen CD80","graph1":"Immunology","graph2":"Phase III","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Beth Israel Deaconess Medical Center","sponsor":"Boston Children's Hospital | Bristol Myers Squibb | Brigham and Women's Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Abatacept","moa":"T-lymphocyte activation antigen CD86 | T-lymphocyte activation antigen CD80","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Beth Israel Deaconess Medical Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Beth Israel Deaconess Medical Center \/ Boston Children's Hospital | Bristol Myers Squibb | Brigham and Women's Hospital","highestDevelopmentStatusID":"7","companyTruncated":"Beth Israel Deaconess Medical Center \/ Boston Children's Hospital | Bristol Myers Squibb | Brigham and Women's Hospital"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Protein","year":"2016","type":"Inapplicable","leadProduct":"Abatacept","moa":"T-lymphocyte activation antigen CD86 | T-lymphocyte activation antigen CD80","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Columbia University","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2013","type":"Inapplicable","leadProduct":"Abatacept","moa":"T-lymphocyte activation antigen CD86 | T-lymphocyte activation antigen CD80","graph1":"Dermatology","graph2":"Phase II","graph3":"Columbia University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Columbia University \/ Bristol Myers Squibb","highestDevelopmentStatusID":"8","companyTruncated":"Columbia University \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Massachusetts General Hospital","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2018","type":"Inapplicable","leadProduct":"Abatacept","moa":"T-lymphocyte activation antigen CD86 | T-lymphocyte activation antigen CD80","graph1":"Immunology","graph2":"Phase II","graph3":"Massachusetts General Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Massachusetts General Hospital \/ Bristol Myers Squibb","highestDevelopmentStatusID":"8","companyTruncated":"Massachusetts General Hospital \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Ono Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2013","type":"Inapplicable","leadProduct":"Abatacept","moa":"T-lymphocyte activation antigen CD86 | T-lymphocyte activation antigen CD80","graph1":"Immunology","graph2":"Phase IV","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Ono Pharmaceutical","highestDevelopmentStatusID":"11","companyTruncated":"Bristol Myers Squibb \/ Ono Pharmaceutical"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2015","type":"Inapplicable","leadProduct":"Abatacept","moa":"T-lymphocyte activation antigen CD86 | T-lymphocyte activation antigen CD80","graph1":"Immunology","graph2":"Phase IV","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2013","type":"Inapplicable","leadProduct":"Abatacept","moa":"T-lymphocyte activation antigen CD86 | T-lymphocyte activation antigen CD80","graph1":"Immunology","graph2":"Phase IV","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2015","type":"Inapplicable","leadProduct":"Abatacept","moa":"T-lymphocyte activation antigen CD86 | T-lymphocyte activation antigen CD80","graph1":"Immunology","graph2":"Phase IV","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Abatacept","moa":"T-lymphocyte activation antigen CD86 | T-lymphocyte activation antigen CD80","graph1":"Immunology","graph2":"Phase IV","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Protein","year":"2015","type":"Inapplicable","leadProduct":"Abatacept","moa":"T-lymphocyte activation antigen CD86 | T-lymphocyte activation antigen CD80","graph1":"Nephrology","graph2":"Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2013","type":"Inapplicable","leadProduct":"Abatacept","moa":"T-lymphocyte activation antigen CD86 | T-lymphocyte activation antigen CD80","graph1":"Immunology","graph2":"Phase IV","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Beth Israel Deaconess Medical Center","sponsor":"Bristol Myers Squibb | Dana-Farber Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Protein","year":"2013","type":"Inapplicable","leadProduct":"Abatacept","moa":"T-lymphocyte activation antigen CD86 | T-lymphocyte activation antigen CD80","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Beth Israel Deaconess Medical Center","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Beth Israel Deaconess Medical Center \/ Bristol Myers Squibb | Dana-Farber Cancer Institute","highestDevelopmentStatusID":"6","companyTruncated":"Beth Israel Deaconess Medical Center \/ Bristol Myers Squibb | Dana-Farber Cancer Institute"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Abatacept","moa":"T-lymphocyte activation antigen CD86 | T-lymphocyte activation antigen CD80","graph1":"Undisclosed","graph2":"Phase I","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Abatacept","moa":"T-lymphocyte activation antigen CD86 | T-lymphocyte activation antigen CD80","graph1":"Undisclosed","graph2":"Phase I","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Melbourne Health","sponsor":"National Health and Medical Research Council, Australia | Juvenile Diabetes Research Foundation","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"AUSTRALIA","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Abatacept","moa":"T-lymphocyte activation antigen CD86 | T-lymphocyte activation antigen CD80","graph1":"Endocrinology","graph2":"Phase II","graph3":"Melbourne Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Melbourne Health \/ National Health and Medical Research Council, Australia | Juvenile Diabetes Research Foundation","highestDevelopmentStatusID":"8","companyTruncated":"Melbourne Health \/ National Health and Medical Research Council, Australia | Juvenile Diabetes Research Foundation"},{"orgOrder":0,"company":"Dinesh Khanna, MD, MS","sponsor":"Bristol Myers Squibb | National Institute of Allergy and Infectious Diseases","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Protein","year":"2014","type":"Inapplicable","leadProduct":"Abatacept","moa":"T-lymphocyte activation antigen CD86 | T-lymphocyte activation antigen CD80","graph1":"Dermatology","graph2":"Phase II","graph3":"Dinesh Khanna, MD, MS","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Dinesh Khanna, MD, MS \/ Bristol Myers Squibb | National Institute of Allergy and Infectious Diseases","highestDevelopmentStatusID":"8","companyTruncated":"Dinesh Khanna, MD, MS \/ Bristol Myers Squibb | National Institute of Allergy and Infectious Diseases"},{"orgOrder":0,"company":"Gabrail Cancer Center Research","sponsor":"Thrasher Research Fund | Sickle Cell Transplant & Research Alliance | Aflac Cancer and Blood Disorders Center | Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Protein","year":"2019","type":"Inapplicable","leadProduct":"Abatacept","moa":"T-lymphocyte activation antigen CD86 | T-lymphocyte activation antigen CD80","graph1":"Immunology","graph2":"Phase II","graph3":"Gabrail Cancer Center Research","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gabrail Cancer Center Research \/ Thrasher Research Fund | Sickle Cell Transplant & Research Alliance | Aflac Cancer and Blood Disorders Center | Bristol Myers Squibb","highestDevelopmentStatusID":"8","companyTruncated":"Gabrail Cancer Center Research \/ Thrasher Research Fund | Sickle Cell Transplant & Research Alliance | Aflac Cancer and Blood Disorders Center | Bristol Myers Squibb"},{"orgOrder":0,"company":"Christopher Bowlus","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"","productType":"Protein","year":"2014","type":"Inapplicable","leadProduct":"Abatacept","moa":"T-lymphocyte activation antigen CD86 | T-lymphocyte activation antigen CD80","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase IV","graph3":"Christopher Bowlus","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Christopher Bowlus \/ Bristol Myers Squibb","highestDevelopmentStatusID":"11","companyTruncated":"Christopher Bowlus \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Orrin M Troum, M.D. and Medical Associates","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Protein","year":"2011","type":"Inapplicable","leadProduct":"Abatacept","moa":"T-lymphocyte activation antigen CD86 | T-lymphocyte activation antigen CD80","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Orrin M Troum, M.D. and Medical Associates","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Orrin M Troum, M.D. and Medical Associates \/ Bristol Myers Squibb","highestDevelopmentStatusID":"9","companyTruncated":"Orrin M Troum, M.D. and Medical Associates \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Rohit Aggarwal, MD","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"","productType":"Protein","year":"2017","type":"Inapplicable","leadProduct":"Abatacept","moa":"T-lymphocyte activation antigen CD86 | T-lymphocyte activation antigen CD80","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Rohit Aggarwal, MD","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rohit Aggarwal, MD \/ Bristol Myers Squibb","highestDevelopmentStatusID":"8","companyTruncated":"Rohit Aggarwal, MD \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"R\u00fcdiger B. M\u00fcller","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Protein","year":"2013","type":"Inapplicable","leadProduct":"Abatacept","moa":"T-lymphocyte activation antigen CD86 | T-lymphocyte activation antigen CD80","graph1":"Immunology","graph2":"Phase IV","graph3":"R\u00fcdiger B. M\u00fcller","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"R\u00fcdiger B. M\u00fcller \/ Bristol Myers Squibb","highestDevelopmentStatusID":"11","companyTruncated":"R\u00fcdiger B. M\u00fcller \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Infliximab","moa":"||TNF-alpha","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"National Institutes of Health \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"National Institutes of Health \/ Undisclosed"},{"orgOrder":0,"company":"Coya Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"Abatacept","moa":"||Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"Coya Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Coya Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Coya Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Coya Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"INDIA","productType":"Protein","year":"2023","type":"Licensing Agreement","leadProduct":"Abatacept","moa":"||Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Coya Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Coya Therapeutics"},{"orgOrder":0,"company":"Coya Therapeutics","sponsor":"Dr. Reddy's Laboratories","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2023","type":"Licensing Agreement","leadProduct":"Abatacept","moa":"||Undisclosed","graph1":"Neurology","graph2":"Phase II","graph3":"Coya Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Coya Therapeutics \/ Dr. Reddy's Laboratories","highestDevelopmentStatusID":"8","companyTruncated":"Coya Therapeutics \/ Dr. Reddy's Laboratories"}]
Find Clinical Drug Pipeline Developments & Deals for Abatacept
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
